Antitumour metal compounds: more than theme and variations.
about
The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozymeAnionic chlorido(triphenyl)tin(IV) bearing N-phthaloylglycinato or 1,2,4-benzenetricarboxylato 1,2-anhydride ligands: potential cytotoxic and apoptosis-inducing agents against several types of cancer.Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.Structural and photophysical studies on gallium(III) 8-hydroxyquinoline-5-sulfonates. Does excited state decay involve ligand photolabilisation?Antitumor activity of new enantiopure pybox-ruthenium complexes.Kinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents.Titanium salan complexes displays strong antitumor properties in vitro and in vivo in miceExploring the cellular accumulation of metal complexes.Medical applications and toxicities of gallium compounds.Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.Synthesis, Structure, and Antiproliferative Activity of Three Gallium(III) Azole ComplexesInteraction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.Organometallic anticancer compoundsBODIPY-phosphane as a versatile tool for easy access to new metal-based theranostics.Mixed ligand μ-phenoxo-bridged dinuclear copper(II) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice.Understanding the interaction of an antitumoral platinum(II) 7-azaindolate complex with proteins and DNA.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity.Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.Novel metals and metal complexes as platforms for cancer therapyDicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution.Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.Bioorganometallic chemistry--from teaching paradigms to medicinal applications.Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.MALDI-TOFMS analysis of coordination and organometallic complexes: a nic(h)e area to work in.Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Fast and slow versus strong and weak metal-DNA binding: consequences for anti-cancer activity.Mechanistic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur-donor biomolecules.Targeting and delivery of platinum-based anticancer drugs.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes.Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.Zn(ii) and Cu(ii) complexes containing bioactive O,O-chelated ligands: Homoleptic and heteroleptic metal-based biomolecules.
P2860
Q27690763-0E917F0B-45F6-44ED-BB0F-6B3676168DD3Q30313823-9BDA9B09-784F-46ED-A717-B580DD929315Q30403317-12B67522-B5E4-4108-9C8D-23A9860A0108Q30585167-6CDD6F32-3851-400C-99F7-515F1824C02DQ30660221-EA1A613C-EFC6-4251-AA3C-A3CAC7FE131FQ30670864-798C5964-B7E1-45F6-8557-91121B3AE92DQ33857149-7CF52067-A6FF-4C48-8F38-16F0364F5D66Q33866011-35C5C736-74B4-4CE3-84D0-46033A7AB4F4Q33965885-0FC23CA3-1B91-442D-9AC1-8DB527B563D9Q34020456-9E914BC7-38E0-49AE-8694-42C01AE5A07CQ34035054-694BF40A-B1F0-465C-A43C-1F1233079ADAQ34327703-3A0CCADC-3046-4C60-B3D6-69F313BEB290Q34415646-0670ABE5-5F64-489B-A25A-8ECCF6B95D75Q34476685-A4BFD0BA-3F5D-4937-A1D4-DABBC2118A5AQ34509157-E6BCF863-0D5E-4D51-AC4E-219F35622061Q35111438-46D79C3C-F94A-4A80-850A-4636D751CA13Q35154374-AE3B996A-1CE6-4C48-A794-7CDCB8E41660Q35167846-AF1FF24D-5003-45DD-A248-1316B3353288Q35222016-5F77CD2A-ACC2-4E7E-A23E-5EAD052342ABQ36086603-BD14E591-13D4-4CCF-9896-D6064A80811FQ36103771-2B01CF70-CB55-40D1-B188-F186AC34B397Q37115673-187268A8-1A06-44A4-88B6-AE5730180AA0Q37137649-BBDF9264-2CB7-463F-AE2D-F469551DFCF7Q37148450-063EAED5-D905-4CF9-915F-B3C8292F54E1Q37169192-F754D6AF-267C-4A60-90C3-4B9E0A5C09A7Q37377528-CA96B8E1-44EA-4A1E-BC37-AA40912C012FQ37382191-904E4D86-5D63-489D-95A4-400EF6E06D81Q37657640-70CB3157-709F-46E3-A169-D2B0E4A93EAFQ37709331-45E68B40-C4F0-4E75-939F-8246D951CD6DQ37808951-87D795CB-0A1F-4058-BC66-950426C4212DQ37899834-9236B594-211C-452D-94DB-BE4E83512DB2Q37997361-DB6B112B-CD10-4237-A5EA-418962EF1A35Q38001300-88A1CAEE-42B9-4F44-A6BB-1935A4C597ECQ38034439-2EEF0C1A-4BF3-4DAE-8877-BB93C1120913Q38050063-D28BAFD3-BBF9-4D17-BD37-144639A97863Q38096196-B02A8E7A-C423-49F4-BA5B-BA450C880D63Q38105454-183A4479-D310-4CF2-BA31-342278422EA3Q38203819-D0648CD1-F7E2-420E-8F90-CEDC4AA11104Q38328481-51D5936B-6967-4FF4-909A-08CD648039A7Q38436960-FF9E2755-E9EF-4BA0-BC7D-9BA72B70EF8A
P2860
Antitumour metal compounds: more than theme and variations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Antitumour metal compounds: more than theme and variations.
@en
Antitumour metal compounds: more than theme and variations.
@nl
type
label
Antitumour metal compounds: more than theme and variations.
@en
Antitumour metal compounds: more than theme and variations.
@nl
prefLabel
Antitumour metal compounds: more than theme and variations.
@en
Antitumour metal compounds: more than theme and variations.
@nl
P50
P356
P1433
P1476
Antitumour metal compounds: more than theme and variations.
@en
P2093
Markus Galanski
Vladimir B Arion
P304
P356
10.1039/B712656P
P407
P577
2007-11-07T00:00:00Z